GB0503434D0 - Amyloid-binding peptides, analogues and uses thereof - Google Patents

Amyloid-binding peptides, analogues and uses thereof

Info

Publication number
GB0503434D0
GB0503434D0 GBGB0503434.3A GB0503434A GB0503434D0 GB 0503434 D0 GB0503434 D0 GB 0503434D0 GB 0503434 A GB0503434 A GB 0503434A GB 0503434 D0 GB0503434 D0 GB 0503434D0
Authority
GB
United Kingdom
Prior art keywords
amyloid
analogues
binding peptides
peptides
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0503434.3A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senexis Ltd
Original Assignee
Senexis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senexis Ltd filed Critical Senexis Ltd
Priority to GBGB0503434.3A priority Critical patent/GB0503434D0/en
Publication of GB0503434D0 publication Critical patent/GB0503434D0/en
Priority to CA002598080A priority patent/CA2598080A1/en
Priority to EP06709776A priority patent/EP1853626A2/en
Priority to PCT/GB2006/000539 priority patent/WO2006087550A2/en
Priority to AU2006215406A priority patent/AU2006215406A1/en
Priority to JP2007555695A priority patent/JP2008530194A/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
GBGB0503434.3A 2005-02-18 2005-02-18 Amyloid-binding peptides, analogues and uses thereof Ceased GB0503434D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB0503434.3A GB0503434D0 (en) 2005-02-18 2005-02-18 Amyloid-binding peptides, analogues and uses thereof
CA002598080A CA2598080A1 (en) 2005-02-18 2006-02-16 Amyloid-binding peptides, analogues and uses thereof
EP06709776A EP1853626A2 (en) 2005-02-18 2006-02-16 Amyloid-binding peptides, analogues and uses thereof
PCT/GB2006/000539 WO2006087550A2 (en) 2005-02-18 2006-02-16 Amyloid-binding peptides, analogues and uses thereof
AU2006215406A AU2006215406A1 (en) 2005-02-18 2006-02-16 Amyloid-binding peptides, analogues and uses thereof
JP2007555695A JP2008530194A (en) 2005-02-18 2006-02-16 Amyloid binding peptides, analogs and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0503434.3A GB0503434D0 (en) 2005-02-18 2005-02-18 Amyloid-binding peptides, analogues and uses thereof

Publications (1)

Publication Number Publication Date
GB0503434D0 true GB0503434D0 (en) 2005-03-30

Family

ID=34400981

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0503434.3A Ceased GB0503434D0 (en) 2005-02-18 2005-02-18 Amyloid-binding peptides, analogues and uses thereof

Country Status (6)

Country Link
EP (1) EP1853626A2 (en)
JP (1) JP2008530194A (en)
AU (1) AU2006215406A1 (en)
CA (1) CA2598080A1 (en)
GB (1) GB0503434D0 (en)
WO (1) WO2006087550A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
AU2006287299B2 (en) 2005-09-09 2012-08-23 Novartis Ag Prion-specific peptoid reagents
PL1954718T3 (en) 2005-11-30 2015-04-30 Abbvie Inc Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
JP5486808B2 (en) 2005-11-30 2014-05-07 アッヴィ・インコーポレイテッド Monoclonal antibody against amyloid beta protein and use thereof
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
JP4777225B2 (en) * 2006-12-04 2011-09-21 キヤノン株式会社 Discharge liquid and discharge method
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
DK2220030T3 (en) * 2007-11-06 2016-04-11 Edison Pharmaceuticals Inc 4- (P-QUINONYL) -2-HYDROXYBUTANAMIDDERIVATER TO TREAT mitochondrial
JP5554528B2 (en) * 2009-09-08 2014-07-23 国立大学法人 岡山大学 Novel amyloid β aggregate-binding peptide and method for testing amyloid disease using the novel amyloid β aggregate-binding peptide
CN104744591B (en) 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 Amyloid beta binding proteins
CN105348387B (en) 2010-08-14 2020-08-25 Abbvie 公司 Amyloid beta binding proteins
WO2013082045A1 (en) * 2011-11-28 2013-06-06 Buck Institute For Age Research Netrin loop peptide mimetics and uses thereof
WO2014184596A2 (en) * 2013-05-17 2014-11-20 Szegedi Tudomanyegyetem SMALL PEPTIDE INHIBITORS OF β-AMYLOID TOXICITY
WO2015043567A1 (en) * 2013-09-26 2015-04-02 Forschungszentrum Jülich GmbH Amyloid-beta-binding peptides and the use thereof for the therapy and diagnosis of alzheimer's dementia
NZ747418A (en) * 2014-03-12 2023-05-26 Yeda Res & Dev Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
CN106800590B (en) 2015-11-25 2021-04-09 杭州智鹤丹谷生物医药有限公司 Polypeptide combining multiple amyloid protein monomers and aggregates and application thereof
US11970521B2 (en) * 2016-08-20 2024-04-30 Arizona Board Of Regents On Behalf Of The University Of Arizona Neuroprotective beta amyloid core peptides and peptidomimetic derivatives
KR101956302B1 (en) * 2016-11-30 2019-03-11 연세대학교 산학협력단 intracellular pH-responsive fusion peptide, phamaceutical composition for treatment of protein aggregation and misfolding related diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303567B1 (en) * 1995-03-14 2001-10-16 Praecis Pharmaceuticals, Inc . Modulators of β-amyloid peptide aggregation comprising D-amino acids
AU781292B2 (en) * 1999-03-04 2005-05-12 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation comprising D-amino acids

Also Published As

Publication number Publication date
EP1853626A2 (en) 2007-11-14
CA2598080A1 (en) 2006-08-24
JP2008530194A (en) 2008-08-07
WO2006087550A8 (en) 2006-12-14
WO2006087550A2 (en) 2006-08-24
WO2006087550A3 (en) 2007-05-24
AU2006215406A1 (en) 2006-08-24

Similar Documents

Publication Publication Date Title
GB0503434D0 (en) Amyloid-binding peptides, analogues and uses thereof
IL261346A (en) Tissue protective peptides and uses thereof
IL209494A (en) Insulin-oligomer monoconjugates, formulations and uses thereof
HK1095045A1 (en) Modified exendins and uses thereof
EP1920216A4 (en) Location signposting and orientation
IL184428A0 (en) Peptides with neuropeptide-2-receptor
GB0508863D0 (en) Peptide
IL185308A0 (en) Replikin peptides and uses thereof
EP1723247A4 (en) Recombinant perforin, expression and uses thereof
IL188611A0 (en) Sp1 polypeptides, modified sp1 polypeptides and uses thereof
IL190781A0 (en) Glp-2 mimetibodies, polypeptides, compositions, methods and uses
EP1863800A4 (en) Synthesis of avrainvillamide, stephacidin b, and analogues thereof
ZA200804502B (en) GLP-2 mimetibodies, polypeptides, compositions, methods and uses
GB0522748D0 (en) Collagen peptides, methods and uses
EP1953227A4 (en) Lipopolysaccharide- or lipid a-binder, and novel peptide
IL177759A0 (en) Cospeptin, cosmedin and their uses
GB0526019D0 (en) Peptides
GB0516527D0 (en) Peptides
GB0520935D0 (en) Integrated processor-template-system and project
EP1939286A4 (en) Novel peptides
GB0516571D0 (en) Novel polypeptides and uses thereof
GB0508726D0 (en) Polypeptide, vaccine and use thereof
GB0517813D0 (en) Peptides and uses thereof
IL242077A0 (en) Sp1 polypeptides, modified sp1 polypeptides and uses thereof
GB0510175D0 (en) New polypeptide, uses thereof and methods employing it

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)